Eli Lilly Q2 2026 Earnings: $23 Billion Revenue, $1 Trillion Market Cap, and the State of the Obesity Drug Race

Last updated: August 7, 2026

Quick answer: Eli Lilly reported $23 billion in second quarter 2026 revenue, with shares rising nearly 5% to $1,170 and a market capitalization of $1.02 trillion. On the same day, Amgen discontinued its Phase 1 obesity candidate AMG 513, leaving MariTide as its only weight loss asset, and Novo Nordisk’s chief executive told analysts that failure is par for the course in drug development.

This reference page covers Lilly’s quarter, the full competitive landscape in obesity drugs, the expansion of GLP-1 medicines into new indications, AstraZeneca’s China manufacturing joint venture, and the other developments of August 6, 2026.

How much revenue did Eli Lilly report in Q2 2026?

Eli Lilly reported $23 billion in second quarter 2026 revenue. Shares rose nearly 5% to $1,170 in premarket trading following the report. The company’s market capitalization stood at $1.02 trillion as of the end of July 2026.

Why the quarter matters beyond the headline number

Lilly’s revenue is the mechanism that funds the most active acquisition program in the pharmaceutical industry. Across 2026 the company has completed eleven company acquisitions, more than any peer, alongside a separate set of licensing agreements and research collaborations.

Those transactions span obesity, oncology, cell and gene therapy, vaccines, pain, and psychedelic medicine. The largest disclosed deal of the year was the acquisition of AtaiBeckley in July 2026 for $2.8 billion upfront and up to $3.8 billion in total consideration, one of the largest moves any major pharmaceutical company has made into psychedelic based mental health treatment.

The structural point is that the obesity franchise generates enough cash to fund continuous acquisition without straining the balance sheet, and those acquisitions build the pipeline that is intended to sustain the company past the current product cycle.

What is Eli Lilly’s obesity drug portfolio?

Lilly is the only company with an asset at every efficacy and format tier of the obesity market. The portfolio spans oral and injectable delivery and moderate through maximum efficacy.

Foundayo, the convenience tier

Foundayo is Lilly’s oral obesity medicine. Its strategic function is to reach patients deterred by injection, a constraint that meaningfully limits the addressable population for injectable GLP-1 medicines. A type 2 diabetes regulatory filing is pending under the Commissioner’s National Priority Voucher pathway.

Zepbound, the commercial engine

Zepbound is tirzepatide, a dual agonist targeting the GIP and GLP-1 receptors. It established the efficacy benchmark against which competing obesity medicines are measured. Its addressable population expanded on July 1, 2026, when the Medicare GLP-1 Bridge program began providing coverage for obesity medicines to a Medicare population previously excluded.

Retatrutide, the maximum efficacy tier

Retatrutide is a first in class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The glucagon component, which contributes to energy expenditure, is the leading explanation for its class leading weight reduction.

Retatrutide clinical and regulatory timeline:

The unresolved question on retatrutide: analysts have noted the data leave open how much the triple hormone mechanism contributes to cardiovascular outcomes specifically, as distinct from the benefit that follows from weight loss alone. Cardiovascular outcomes data is what anchors premium reimbursement and treatment guideline placement, so this element of the case is not yet complete.

Why did Amgen discontinue AMG 513?

Amgen discontinued AMG 513, a Phase 1 obesity candidate, as part of a portfolio prioritization. The decision leaves MariTide as Amgen’s only remaining weight loss asset. Executives stated the company’s late stage pipeline is largely full and that future business development will focus on earlier stage opportunities.

Why the stated shift toward earlier stage deals is significant

The discontinuation itself is routine. The strategic disclosure accompanying it is not.

A statement that business development will target earlier stage assets indicates a judgment that competing for late stage obesity programs is not a productive use of capital. Late stage obesity assets currently command premium valuations while still measuring unfavorably against tirzepatide and retatrutide on efficacy. The implication is that the remaining opportunity lies in mechanisms that have not yet been de risked and are therefore not yet priced at a premium.

This has a direct read through to the financing environment. Throughout 2026, capital has concentrated heavily in late stage and commercial assets while early stage companies have faced the most difficult fundraising conditions in years. Approximately two thirds of venture rounds in the first half of 2026 went to companies that already had a drug in human testing. A shift in large cap business development toward earlier stage assets, if it extends beyond Amgen, would begin to correct that imbalance, and obesity is the logical place for the correction to begin because the commercial prize is large enough to justify earlier risk.

Who is winning the obesity drug race in 2026?

Eli Lilly leads the obesity market on efficacy, portfolio breadth, and revenue growth. Novo Nordisk remains the largest scale competitor but has experienced consecutive setbacks in 2026. Roche, Amgen, Arrowhead, and Pfizer occupy varying positions further back.

A note on the Arrowhead interim data

Arrowhead’s ARO-INHBE readout, which showed approximately double the weight loss of tirzepatide, came from a small number of patients in early stage work. Interim signals from small samples frequently attenuate in larger, better controlled trials. The result is a signal worth tracking rather than a basis for repositioning views of the market.

The mechanistic distinction is nonetheless real. Arrowhead’s programs use RNA interference to silence specific genetic targets, a fundamentally different modality from the peptide receptor agonists that dominate the market today. Analysts at Jefferies have described Arrowhead as ahead of peers across its INHBE and ALK7 obesity programs.

Novo Nordisk’s 2026 setbacks in sequence

Novo also secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie, ordering an immediate halt to sales of a compounded semaglutide nasal spray found to infringe Novo’s intellectual property.

Can GLP-1 drugs treat alcohol use disorder?

Altimmune reported that pemvidutide, a GLP-1 and glucagon receptor agonist, produced a highly statistically significant treatment effect in alcohol use disorder. Larger controlled trials are required before the effect can be considered established. Eli Lilly and Baseline Therapeutics are also developing candidates in the indication.

The mechanistic rationale

GLP-1 receptor agonists act centrally, on the brain circuits governing appetite, reward, and craving, not solely on peripheral metabolism. The working hypothesis is that a medicine that reduces the drive to eat may also reduce the drive to drink. Patient reports of diminished alcohol interest while taking these medicines circulated well before controlled data existed.

The caution is that behavioral and neuropsychiatric endpoints are difficult to measure reliably, and mid stage signals in these settings attenuate more often than in other therapeutic areas.

How far the GLP-1 class has expanded

What is the AstraZeneca CSPC joint venture?

AstraZeneca and China’s CSPC Pharmaceutical signed a joint venture contract to construct a new generation biologics manufacturing facility in Shijiazhuang, China, deepening an existing strategic collaboration between the two companies.

Why a manufacturing joint venture is structurally different

AstraZeneca’s prior China transactions acquired molecules through licensing. A manufacturing joint venture builds fixed assets inside the country, which represents a longer commitment and is considerably more difficult to unwind than a licensing agreement.

AstraZeneca China transactions, 2026:

AstraZeneca has signed more licensing agreements with Chinese drugmakers since the start of 2025 than any major pharmaceutical company other than Roche.

The regulatory backdrop

In June 2026 the House Select Committee on China opened an inquiry into the China clinical trials conducted by Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb, requesting documentation on data protection, intellectual property safeguards, informed consent, and site oversight, with responses due July 17, 2026. The committee stated it had found no evidence of illegal activity. AstraZeneca was not among the companies named.

The Biotech Investment National Security Act, introduced by Representatives John Moolenaar and Debbie Dingell, would add biotech licensing agreements, joint ventures, and equity investments involving Chinese firms to the categories of transaction subject to US Treasury review. The bill awaits a committee vote.

Other developments, August 6, 2026

Merck seeks a second season indication for its RSV antibody

The FDA accepted Merck’s supplemental Biologics License Application for Enflonsia (clesrovimab-cfor), seeking to expand the indication to children under two years old at increased risk of severe respiratory syncytial virus disease through their second RSV season.

Most existing RSV prophylaxis targets infants during their first season. Children who remain at elevated risk currently age out of protection, and the filing addresses that gap.

Gilead’s HIV franchise leads the quarter

HIV remained Gilead’s strongest franchise in the second quarter. The company continues building its pipeline beyond virology, with particular emphasis on inflammation and oncology.

Biogen frames its Alzheimer’s program on a 2030 horizon

Biogen is treating diranersen as a high risk, high reward program with a potential major payout around 2030. Chief executive Chris Viehbacher has declined to commit the company fully to the program despite the tau reduction data presented at the Alzheimer’s Association International Conference in July 2026.

That data showed an unprecedented reduction in tau, the protein forming neurofibrillary tangles that correlate closely with cognitive decline, while the study missed its primary endpoint. The result validated the anti tau mechanism without establishing clinical benefit, and Biogen shares fell 8% on the fuller dataset.

MapLight hits its endpoint in schizophrenia

MapLight Therapeutics’ oral schizophrenia candidate met the main endpoint of a Phase 2 trial. Analysts nonetheless expect Bristol Myers Squibb’s Cobenfy to retain market share, reflecting the difficulty of displacing an established medicine in central nervous system disease even with positive data.

Additional items

• Sarepta Therapeutics faces several decisive moments as Michael Severino takes over as chief executive of the Duchenne muscular dystrophy gene therapy company.
• Mironid, based in Glasgow, raised $46 million in Series B financing for small molecule treatments targeting autosomal dominant polycystic kidney disease.
• Marengo Therapeutics nominated its first development candidate under its TriSTAR strategic collaboration with Ipsen and appointed Saso Cemerski as senior vice president, head of immunology.
• Actimed Therapeutics regained exclusive global rights to S-oxprenolol, an anabolic catabolic transforming agent, from Faraday Pharmaceuticals.
• BioSpace launched a dashboard tracking US biotech initial public offerings in 2026, a year on pace for the highest IPO count since 2021.

Frequently asked questions

How much did Eli Lilly make in Q2 2026?

Eli Lilly reported $23 billion in revenue for the second quarter of 2026. Shares rose nearly 5% to $1,170 in premarket trading, and the company’s market capitalization was $1.02 trillion as of the end of July 2026.

What is Eli Lilly’s market cap?

Eli Lilly’s market capitalization was $1.02 trillion as of the end of July 2026.

How many companies has Eli Lilly acquired in 2026?

Eleven, more than any other pharmaceutical company, alongside a separate set of licensing agreements and research collaborations. The acquisitions span obesity, oncology, cell and gene therapy, vaccines, pain, and psychedelic medicine.

What is retatrutide and how does it work?

Retatrutide is a first in class triple hormone receptor agonist targeting the GIP, GLP-1, and glucagon receptors. The glucagon component contributes to energy expenditure and is the leading explanation for its class leading weight reduction, approximately 28% in Phase 2 and above 20% at 80 weeks in pivotal trials.

When will retatrutide be approved?

Eli Lilly has confirmed a regulatory filing in the first quarter of 2027, pulled forward from earlier expectations. Launch is anticipated during 2027. Approval timing depends on FDA review following the filing.

What obesity drugs does Amgen have?

MariTide is Amgen’s only remaining weight loss asset following the discontinuation of the Phase 1 candidate AMG 513. Amgen executives have said future business development will focus on earlier stage opportunities.

Why did Amgen stop developing AMG 513?

Amgen discontinued AMG 513 as part of a portfolio prioritization. Executives described the late stage pipeline as largely full and indicated that future business development will target earlier stage assets, implying a judgment that competing for late stage obesity programs is not the productive route.

Is Novo Nordisk losing to Eli Lilly?

Novo Nordisk has experienced consecutive setbacks in 2026, including a Wegovy pill stumble, a delay to CagriSema Phase 3 data, and the failure of the ziltivekimab cardiovascular outcomes trial. Eli Lilly currently leads on efficacy, portfolio breadth, and revenue growth. Novo retains a large and durable semaglutide franchise, established prescriber relationships, and significant scientific capability.

What happened to ziltivekimab?

Novo Nordisk’s IL-6 inhibitor ziltivekimab failed the ZEUS cardiovascular outcomes Phase 3 trial in early August 2026. Novo shares fell more than 9%. The result was a setback for the hypothesis that directly targeting inflammation can reduce cardiovascular events.

Can Ozempic or Wegovy help with drinking?

Controlled data are still emerging. Altimmune’s pemvidutide, a GLP-1 and glucagon receptor agonist, showed a highly statistically significant treatment effect in alcohol use disorder. The mechanistic rationale is that GLP-1 medicines act on central reward and craving circuitry. Larger trials are required before the effect can be considered established, and no GLP-1 medicine is approved for alcohol use disorder.

What is Enflonsia?

Enflonsia (clesrovimab-cfor) is Merck’s respiratory syncytial virus antibody. The FDA has accepted a supplemental filing seeking to expand the indication to children under two years old at increased risk of severe RSV disease through their second RSV season.

What is the Biotech Investment National Security Act?

Proposed US legislation, introduced by Representatives John Moolenaar and Debbie Dingell, that would add biotech licensing agreements, joint ventures, and equity investments involving Chinese firms to the categories of transaction subject to US Treasury review. It awaits a committee vote.

Which pharmaceutical companies do the most deals with Chinese biotechs?

Roche has signed the most licensing agreements with Chinese drugmakers since the start of 2025, followed by AstraZeneca. AstraZeneca’s 2026 transactions include agreements with CSPC Pharmaceutical, Sino Biopharmaceutical, and Dizal Pharmaceutical, plus a biologics manufacturing joint venture in Shijiazhuang.

Sources

All figures in this piece are drawn from reporting published August 6, 2026, unless otherwise dated.

• Eli Lilly Q2 2026 results, Amgen AMG 513 discontinuation, Novo Nordisk earnings call, Gilead Q2, Biogen diranersen, MapLight Phase 2, Altimmune alcohol use disorder data — BioSpace, August 6, 2026
• Merck Enflonsia sBLA acceptance, AstraZeneca and CSPC joint venture, Novo Nordisk Hague injunction, Mironid Series B, Marengo and Ipsen, Actimed — The Pharma Letter, August 6, 2026
• Sarepta leadership transition — Fierce Pharma, August 6, 2026
• Retatrutide TRIUMPH-2 and TRIUMPH-3 results — The Pharma Letter, July 24, 2026
• Retatrutide filing timing and cardiovascular question — BioPharma Dive, July 29, 2026
• Arrowhead ARO-INHBE interim data and plozasiran Phase 3 — BioSpace, July 30, 2026
• House Select Committee on China inquiry — Committee correspondence and contemporaneous trade reporting, June and July 2026

Related BioMed Nexus coverage

• Retatrutide vs. CagriSema: Why 2026 is the Year of the Triple Agonist
• AstraZeneca and BMS Reportedly Weigh a $400B Merger
• Supernus and Indivior Are Merging Into a CNS Powerhouse
• Cobenfy’s First Year: A Quiet Revolution in Schizophrenia Treatment
• 25 AI Drug Discovery Companies Actually Delivering Clinical Candidates (2026)

BioMed Nexus delivers daily life sciences intelligence to executives, investors, and clinicians. The daily briefing carries the strategic read behind the developments that matter.

© 2026 BioMed Nexus. All rights reserved.